Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

MINNEAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,310,890 shares of the Company’s common stock at a price of $2.59 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.